Adipocytes express all components of the renin-angiotensin system (RAS), and adipocyte RAS regulates adipocyte differentiation and metabolism. Plasma angiotensin (A ) is a putative marker of adipocyte RAS production. The aim of this study was to investigate the effect of pioglitazone on plasma A in type 2 diabetes (T2D). Methods: Fifty Japanese subjects with T2D were randomly allocated to two groups. One group was administered pioglitazone 30 mg/day (pioglitazone group) and the other group was not given pioglitazone (control group) for 16 weeks. Lipoprotein lipase mass in preheparin serum (LPL mass) was measured as an adipocyte-derived factor and a marker of insulin sensitivity. Results: In the pioglitazone group, the mean HbA1c decreased ( p 0.0001), LPL mass increased ( p 0.0001), and plasma A decreased ( p 0.0007), whereas these parameters were unchanged in the control group. The change in plasma A correlated negatively with the change in LPL mass (r 0.312) in the pioglitazone group. In the pioglitazone group, the decrease in plasma A was higher ( p 0.0002) and the increase in LPL mass tended to be higher ( p 0.0941) in the subgroup with higher baseline plasma A than that with lower plasma A . Conclusions: The present study indicates that pioglitazone decreases plasma A associated with an increase in LPL mass in T2D. The insulin-sensitizing effect of pioglitazone may be involved in suppressing adipocyte RAS. J Atheroscler Thromb, 2010; 17:651-657.
Introduction
Recently, it has become evident that inhibition of the renin-angiotensin system (RAS) improves many risk factors, including hypertension, metabolic disorders, and insulin resistance, and prevents the progression of cardiovascular and chronic kidney diseases 1) . On the other hand, adipocytes are known to express all components of the RAS, such as angiotensinogen, renin, angiotensin-converting enzyme (ACE), and chymase, which are required for conversion to angiotensin (A ) 2, 3) . Although A is detectable in the blood, the relationship between circulating A and the components of RAS from adipocytes is completely unknown. We have recently reported that plasma A is associated with body weight, showing a decline during weight loss, and is associated with insulin resistance in obese subjects with type 2 diabetes (T2D) 4) . These findings suggest that A may have a potent metabolic effect on adipose tissue and/or plasma A may be a useful marker of RAS production from adipose tissue.
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is expressed at high levels in adipose tissue, where it plays a central role in adipose tissue functions 5) . Pioglitazone, an oral insulin-sensitiz-ing thiazolidinedione agent, is used for the treatment of T2D. This drug activates nuclear PPAR-gamma, leading to increased transcription of various proteins in adipocytes to improve glucose and lipid metabolism [6] [7] [8] [9] . Clinical studies have suggested that treatment with pioglitazone in T2D subjects significantly increases lipoprotein lipase mass in preheparin serum (LPL mass) 10) . LPL mass reflects lipoprotein lipase (LPL) production from adipocytes 11) , and is a marker of insulin sensitivity [12] [13] [14] [15] [16] [17] . Our in vitro study has shown that A inhibits adipogenic differentiation of 3T3-L1 cells, and the inhibitory effect is reversed by pioglitazone 18) . Furthermore, other investigators have reported that the thiazolidinedione agent rosiglitazone decreases both angiotensinogen protein expression in isolated human subcutaneous adipocytes and A release from the cells 19) . These findings suggest that the beneficial effects of pioglitazone on glucose and lipid metabolism as well as insulin sensitivity may be due to the reduced production of adipocyte RAS components; however, the effect of pioglitazone on circulating RAS components has not been investigated in clinical study.
The aim of this study was to clarify the effect of pioglitazone on plasma A , which may be a marker of adipocyte RAS, and various metabolic parameters in subjects with T2D.
Subjects and Methods

Subjects
This randomized, open study was conducted at the Center of Diabetes, Endocrinology and Metabolism, Toho University Sakura Medical Center. Fifty Japanese subjects (29 males and 21 females) with T2D who had not been treated with pioglitazone were eligible for enrollment. Subjects with diabetic retinopathy, renal dysfunction, including diabetic nephropathy, congestive heart failure, coronary heart disease, and abnormal liver dysfunction (transaminases greater than twice the upper limit of normal) were excluded. The other exclusion criterion was serious systemic diseases, such as acute/chronic inflammation and malignancies. Before pioglitazone administration, 34 subjects had been treated with sulfonylureas and 12 with metformins, which also have an insulin-sensitizing effect. The same doses of sulfonylureas were continued during pioglitazone administration, but sulfonylureas were reduced or discontinued when hypoglycemia occurred. Subjects treated with ACE inhibitor and/or angiotensin type 1 receptor blocker were excluded, because plasma A is highly sensitive to these drugs. Randomization was performed with sequentially numbered, sealed envelopes using a previously determined code for the administration of pioglitazone. One group was administered pioglitazone 30 mg/day (pioglitazone group, n 25) and the other group was not given pioglitazone (control group, n 25) for 12 weeks. Clinical characteristics of the subjects are shown in Table 1 . Dietary counseling was provided by a nutritionist and subjects were asked to avoid any change in their diet or lifestyle during the study period. The study was approved by the Ethics Committee of Toho University, and all subjects provided written informed consent prior to participation in the study.
Body weight, blood pressure and blood sampling
Body weight was measured after an overnight fast. Blood pressure was measured in a sitting position after 5-minute rest in the morning. Blood samples were taken in the morning after 12 hours of fasting and 30-minute rest in the supine position. For plasma A and hemoglobin A1c (HbA1c) measurements, blood was collected into an EDTA tube. Serum was separated within 1 hour for LPL mass, glucose, lipoprotein and other measurements. Samples for plasma A and LPL mass measurement were frozen at 80 until assay.
Plasma A assay
Plasma A was measured by a radioimmunoassay (RIA) (Mitsubishi Chemical Medience Corporation, Tokyo, Japan) 20) . In brief, 0.5 mL plasma sample was collected into a syringe containing 2.5 mL EDTA and prechilled ethanol. The sample was centrifuged and extracted. After purification, immunoreactive A was measured in duplicate by a radioimmunoassay using anti-A antiserum followed by iodinated A ( 125 I-A ) and goat anti-rabbit antiserum as the second antibody.
LPL mass assay
LPL mass was measured by a sandwich enzymelinked immunosorbent assay (ELISA) using a specific monoclonal antibody against bovine milk LPL, as described by Kobayashi et al. 21) . A commercial kit (Sekisui Medical Co. Ltd, Tokyo, Japan) was used in this study. In this assay system, linearity was observed from 5 to 400 ng/mL. The within-run coefficient of variation (Cv) was 2.8%, and between-day Cv was 4.3%.
Statistical Analysis
Data are expressed as the mean S.D. SPSS 15.0 software (SPSS Inc., Chicago, Ill, USA) was used for all statistical analysis. Student's t-test was performed to determine whether differences in levels between groups at baseline, week 16, and during the study were statistically significant. The paired t-test was performed to determine whether differences between levels at baseline and week 16 in each group were statistically significant. A p value less than 0.05 was considered significant.
Results
Table 1
shows the clinical variables of the 50 subjects with T2D in the study. There were no significant differences in all parameters between pioglitazone and control groups at baseline. None of the subjects developed marked edema or other adverse effects, such as cardiac failure, during this study.
Changes in body weight, blood pressure, and glucose and lipid parameters after treatment
First, we confirmed the effect of pioglitazone on body weight, blood pressure, and glucose and lipid parameters. In the pioglitazone group, the mean BMI increased by 2.5% ( p 0.0001), HbA1c decreased by 13.3% ( p 0.0001) and LPL mass increased by 16.6% ( p 0.0001) after 16 weeks of treatment (Table 1) . Blood pressure, and fasting blood glucose and lipid parameters were unchanged. In contrast, all parameters were unchanged in the control group. The increase in BMI, increase in LPL mass and decrease in HbA1c in the pioglitazone group were significant ( p 0.0001 for all) when comparing changes in pioglitazone and control groups ( Table 2) .
Change in plasma A and the relationship between plasma A and various parameters
The mean plasma A at baseline was 10.75 5.41 pg/dL in all subjects. In the pioglitazone group, the mean plasma A decreased by 20.8% ( p 0.0007) after 16 weeks of treatment, whereas no change was observed in the control group ( Table 1) . The decrease in A in the pioglitazone group was significant ( p 0.0001 for all) when comparing changes in pioglitazone and control groups ( Table 2 ). No significant difference was shown in changes in plasma A between subjects treated with and without metformins (data not shown).
We also examined the correlation of the change in plasma A with the changes in body weight, blood pressure, glucose and lipid parameters in the pioglitazone group ( Table 2 ). The change in plasma A correlated negatively with the change in LPL mass ( r 0.312, p 0.0389) (Fig. 1) . Although the mean BMI and HbA1c changed significantly in the pioglitazone group, the changes in these parameters did not correlate with the change in plasma A . 
Changes in various parameters in subjects with high plasma A concentration
To clarify the influence of plasma A on the metabolic effect of pioglitazone, we divided the subjects in the pioglitazone group into two subgroups according to the mean plasma A at baseline (11.96 pg/ dL); lower A (plasma A 12 pg/dL, n 17) and higher A (plasma A ≥ 12 pg/dL, n 8). There were no significant differences in various parameters, except for plasma A , between pioglitazone and control groups at baseline ( Table 3) . The mean plasma A levels at baseline were 9.22 pg/dL in the lower A subgroup and 19.00 pg/dL in the higher A subgroup.
The decrease of fasting blood glucose in the high A group was significant higher than in the low A subgroup ( p 0.0401, data not shown). In the higher A subgroup, the decrease in plasma A was greater ( p 0.0002) ( Fig. 2A) and the increase in LPL mass tended to be greater ( p 0.0941) (Fig. 2 B) than in the lower A subgroup. There were no differences in the changes in other parameters between higher and lower A subgroups.
Discussion
The aim of this study was to investigate the effect of pioglitazone on plasma A , a marker of RAS production from adipose tissue. First, we confirmed the effects of pioglitazone on body weight, blood pressure, and glucose and lipid metabolism. This study showed that pioglitazone treatment for 16 weeks increased BMI and decreased HbA1c. These results are consistent with previous reports on Japanese subjects with T2D 10, 22) . Numerous studies have revealed that pioglitazone is typically associated with weight gain and an increased risk of edema. None of the subjects developed marked edema during this study; therefore, we considered that this study had high reliability to evaluate the effect of pioglitazone on adipose tissue metabolism. In our previous report, based on the findings that plasma A is associated with body weight, visceral fat area, adipocyte-derived factors and insulin resistance, and that A decreases during weight loss in obese subjects with T2D, we concluded that plasma A may reflect the production of RAS components from adipose tissue 4) . In this study, pioglitazone treatment decreased plasma A markedly by 20%. This is the first report of the effect of thiazolidinediones on circulating RAS components in a clinical study, although an in vitro study has shown that rosiglitazone downregulates RAS expression and production in human adipocytes 19) . Some studies have reported the relationship between PPAR-gamma and RAS in adipocytes 23) ; however, the mechanism by which pioglitazone downregulates RAS in adipocytes is still unknown. Therefore, to investigate the relationship between plasma A and adipocyte function, we also measured an adipocyte-derived factor, LPL mass, together with plasma A . On the other hand, angiotensinogen is synthesized primarily by the liver, and is secreted into the circulation, where it is cleaved by renin, which is produced mainly by juxtaglomerular cells, to angiotensin . Angiotensin is subsequently converted to A by ACE from the lungs and endothelial cells 3, 24) ; therefore, plasma A may be regulated by not only adipocytes, but also many cells and organs. A limitation of this study is the origin of plasma A . Recent studies have shown that intrarenal A levels may contribute to the development of hypertension; however, intrarenal A levels have no association with circulating Ang levels 25, 26) . No report has mentioned the relationship among the liver, lung and plasma A ; however, we emphasize that plasma A may reflect the production of RAS components from adipose tissue, since plasma A is associated with body fat composition and adipocyte-derived factors.
We and other investigators have reported that the LPL mass reflects LPL production, particularly in adipocytes, and that low LPL mass reflects increased fat accumulation and insulin resistance 11-15, 27, 28) . In a previous diet-induced weight loss study, we also showed that increased LPL mass is associated with decreased plasma A 4)
. Our in vitro study also showed that the addition of A peptide to the culture medium suppresses LPL activity and expression in 3T3-L1 cells 18) . In adipocytes, the LPL gene is regarded as a target gene of PPAR-gamma 11, 29) ; therefore, A may downregulate LPL expression and production through the suppression of PPAR-gamma in adipocytes. On the other hand, pioglitazone treatment in this study increased the LPL mass, consistent with a previous report 10) . It is obvious that pioglitazone upregulates LPL mass through the activation of PPAR-gamma in adipocytes and increases insulin sensitivity. The salient findings of this study are a negative correlation between the change in LPL mass and plasma A , and the tendency toward a greater LPL mass-enhancing effect of pioglitazone in subjects with higher plasma A . Therefore, we assume that pioglitazone may have two types of PPAR-gamma-enhancing mechanisms; a direct effect on PPAR-gamma and an indirect effect by suppressing RAS in adipocytes, and both mechanisms consequently increase LPL mass.
In diabetes, RAS is thought to play an important role in the regulation of hemodynamics and also in the development of complications, such as diabetic nephropathy 30) ; however, the plasma A level in T2D has not been fully investigated. We have reported that fasting blood glucose and HbA1c do not correlate with plasma A in subjects with T2D 4)
. Nicola et al. 31) have reported that plasma A is lower in non-complicated T2Ds compared to healthy controls, and higher in T2Ds with nephropathy compared to non-complicated T2Ds. In this study, although pioglitazone decreased HbA1c significantly, the decrease in HbA1c did not correlate with the decrease in plasma A ; therefore, the effect of pioglitazone on decreasing plasma A may be independent of its glucose-lowering effect.
In summary, we investigated the effect of pioglitazone on plasma A , a putative marker of adipocytes RAS, and various metabolic parameters in subjects with T2D. Pioglitazone treatment for 16 weeks resulted in a decrease in plasma A correlating with an increase in LPL mass, which is a marker of LPL production from adipocytes and insulin sensitivity. These results suggest that the insulin-sensitizing effect of pioglitazone may be involved in suppressing RAS in adipocytes. 
